Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4.9% | 12.1% | 4.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.4% | 89.8% | 86.3% | 90.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 50.1% | 40.2% | 48.5% | 12% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 42.9% | 30.7% | 37.4% | 2.4% |
| EPS Diluted | 0.23 | 0.15 | 0.16 | 0.01 |
| % Growth | 53.3% | -6.3% | 1,500% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |